Cancer Family
Thymus Neoplasm
CI-CAN-00000366Explore in graph →
Non-malignant104 active trials1 approved drugs1 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000366Explore in graph →
Clinical trials
283 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06311955 | Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor | recruiting | Phase 2 | 48 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06311968 | The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor | recruiting | Phase 2 | 55 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05667948 |
| Molecular Analysis and Treatment Options of Thymic Malignancies |
| recruiting |
| — |
| 500 |
| Shanghai Chest HospitalOTHER |
| 1 |
| May 22, 2025 |
| clinicaltrials |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT05377307 | Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy | recruiting | — | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06871007 | Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma | enrolling by invitation | Phase 1 / Phase 2 | 22 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06093841 | Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | active not recruiting | Phase 2 | 46 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06464861 | Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma(CD19-CARNK/T) | recruiting | Phase 1 | 52 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06781450 | Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context(PRIMICI) | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06796517 | Immunotherapy in Lymphoma | recruiting | — | 72 | Sung-Soo ParkOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06750952 | Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial(iTHYM) | not yet recruiting | Phase 2 | 24 | Sun Yat-sen UniversityOTHER | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06730308 | Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma | recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06692062 | Hypofractionated Radiotherapy for Thymic Epithelial Tumors | recruiting | N/A | 100 | Rongrong ZhouOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06654830 | RATT Vs. VATT for Early-stage TETs | not yet recruiting | Phase 2 | 100 | Shanghai Zhongshan HospitalOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT05683886 | A Study of KC1036 in Patients with Advanced Thymic Tumors | recruiting | Phase 2 | 30 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05202782 | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | active not recruiting | Phase 2 | 24 | Northwestern UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06238648 | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | recruiting | Phase 2 | 120 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT04049513 | ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)(ENABLE-1) | active not recruiting | Phase 1 | 30 | Malaghan Institute of Medical ResearchOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06523582 | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients | recruiting | — | 750 | Universidad Nacional Autonoma de MexicoOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT05682742 | Clinical Investigation of the da Vinci Surgical System | active not recruiting | N/A | 53 | Intuitive SurgicalINDUSTRY | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06421805 | Establishing Prospective Mediastinal Tumor Database of PUMCH(MTDPUMCH) | recruiting | — | 2,000 | Peking Union Medical College HospitalOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06200233 | Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor | not yet recruiting | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06339255 | Italian Observational Study on CAR-T Therapy for Lymphoma(CART-SIE) | recruiting | — | 5,300 | Paolo CorradiniOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06301945 | Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors(INTHYM) | recruiting | — | 1,020 | Erasmus Medical CenterOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06029621 | Robot-assisted vs VATS for Thymoma | recruiting | N/A | 304 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05832827 | First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)(Artemis) | recruiting | Phase 2 | 35 | National Cancer Center, JapanOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN) | active not recruiting | Phase 1 | 21 | Tessa TherapeuticsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04824950 | Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)(CAMIL) | recruiting | N/A | 87 | Centre Henri BecquerelOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04822077 | Study on Proton Radiotherapy of Thymic Malignancies(PROTHYM) | recruiting | N/A | 40 | Ass. Prof. Jan NymanNETWORK | 1 | Mar 30, 2021 | clinicaltrials |
| NCT04522687 | Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer | recruiting | — | 500 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Aug 21, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jun 13, 2025source: clinicaltrials